Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $1.94B | $3.24B | -39.93% |
Cost of Revenue | $868M | $1.46B | -40.71% |
Operating Income | $-3.07B | $-3.94B | +22.08% |
Net Income | $-2.82B | $-3.56B | +20.75% |
EPS (Basic) | $-7.26 | $-9.28 | +21.77% |
EPS (Diluted) | $-7.26 | $-9.28 | +21.77% |
R&D Expense | $3.13B | $4.54B | -31.06% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $12.34B | $14.14B | -12.76% |
Current Assets | $6.54B | $8.1B | -19.20% |
Total Liabilities | $3.69B | $3.24B | +13.79% |
Current Liabilities | $1.99B | $2.21B | -9.93% |
Stockholders' Equity | $8.65B | $10.9B | -20.65% |
Cash & Equivalents | $2.6B | $1.93B | +34.67% |
Long-Term Debt | $590M | $0 | — |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $-1.87B | $-3B | +37.65% |
Investing Cash Flow | $1.95B | $1.95B | -0.15% |
Financing Cash Flow | $593M | $56M | +958.93% |
Share Buybacks | $2M | $0 | — |
D&A | $211M | $185M | +14.05% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | -158.1% | -121.9% | -36.22% |
Net Margin | -145.2% | — | — |
ROE | -32.6% | — | — |
ROA | -22.9% | — | — |
Current Ratio | $3.293 | — | — |
Debt to Equity | $0.426 | — | — |
MRNA's 2025 fiscal year results show a significant decline in revenue and continued net losses, but improved cash flow from operations and a strengthened cash position.
MRNA experienced a 39.9% decrease in revenue, primarily due to reduced demand for its COVID-19 vaccine as the pandemic subsided.
Source: Source: 10-K Income Statement
Despite negative net income, operating cash flow improved by 37.6%, indicating better cash management and reduced operational expenses.
Source: Source: 10-K Cash Flow Statement
Cash and equivalents increased by 34.7%, providing a stronger liquidity position to support future R&D and operational needs.
Source: Source: 10-K Balance Sheet
MRNA's revenue is heavily reliant on its COVID-19 vaccine, and any further decline in demand could significantly impact financial performance.
Source: Source: 10-K Income Statement
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology